Active Filter(s):
Details:
JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: JanOne
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2020